|D003093||Colitis, Ulcerative NIH||1.00|
|D015212||Inflammatory Bowel Diseases NIH||0.38|
There is one clinical trial.
Whether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes
Description: The need for in-hospital colectomy or rescue therapyMeasure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy Time: 3 months
Description: Duration and type/route of steroid useMeasure: 2.1: Duration and type/route of steroid use Time: 3 months
Description: 30 day colectomy free survival ratesMeasure: 2.2: 30 day colectomy free survival rates Time: 3 months
Description: Covid-19 infection ratesMeasure: 2.3: Covid-19 infection rates Time: 3 months
Description: Rate of Rescue therapy useMeasure: 2.4: Rate of Rescue therapy use Time: 3 months
Description: Duration of hospital stayMeasure: 2.5: Duration of hospital stay Time: 3 months
Description: Admission severity scoringMeasure: 2.6: Admission severity scoring Time: 3 months
Description: Readmission ratesMeasure: 2.7: Readmission rates Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports